Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients

Diabetes

Volumn 50, Issue 3, 2001, Pages 609-613

  Vilsbøll, Tina ^a,b   Krarup, Thure ^a   Deacon, Carolyn F ^b   Madsbad, Sten ^c   Holst, Jens J ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; DIPEPTIDYL PEPTIDASE; GLUCAGON LIKE PEPTIDE 1; INSULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOTHESIS; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; TEST MEAL;

EID: 0001095690     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.50.3.609     Document Type: Article

References (31)

1. Gut hormones and diabetes mellitus
2. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene
3. Additive insuli-notropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations
4. Degradation of endogenous and exogenous gastric inhibitory polypeptide (GIP) in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
5. 2-terminus in type II diabetic patients and in healthy subjects
6. The enteroinsular axis in dipeptidyl peptidase IV-negative rats
7. Dipeptidyl-peptidase IV(CD26): Role in the inactivation of regulatory peptides
8. Identification and actions of gastric inhibitory polypeptide
9. Glucagonlike peptide 1 (7-37) actions on endocrine pancreas
10. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig
11. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
12. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
13. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation
14. Radioimmunological determination of human C-peptide in serum
15. Characterization of seven C-peptide antisera
16. Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics
17. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera
18. Synthetic peptides as antigen
19. Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet
20. Proglucagon processing in porcine and human pancreas
21. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
22. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans
23. Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP)
24. GLP-1 secretion is decreased in NIDDM patients compared to matched control subjects with normal glucose tolerance
25. The effect of exogenous GLP-1 on the glucose mediated insulin secretion: A dose-response study in patients with type 2 diabetes mellitus and control subjects
26. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
27. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM): Evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins
28. Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of type II (non-insulin-dependent) diabetic parents: Evidence of several aberrations
29. The glucagon-like peptides
30. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine
31. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-eterminally truncated peptide that is a major endogenous metabolite in vivo